Ainos Reports Breakthrough Interim Results in VELDONA Clinical Trial for FCGS, Signaling New Era in Companion Animal Immunotherapy

May 19, 2025 8:00 AM

Ainos, Inc. (Nasdaq:AIMD)(Nasdaq:AIMDW) ("Ainos"), a pioneer of low-dose oral interferon therapeutics, today announced compelling interim results from its ongoing veterinary clinical trial using low-dose interferon VELDONA for treating Feline Chronic Gingivostomatitis ("FCGS"), a chronic inflammatory conditions in cats. The interim results demonstrate meaningful improvements in inflammation and a consistent reduction in steroid dependency,...

Read more

Interactive Strength Inc. (Nasdaq: TRNR) Reports First Quarter 2025 Results, Increases 2025 Pro Forma Revenue Guidance to more than $75M

May 19, 2025 8:00 AM

Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or the "Company"), maker of innovative specialty fitness equipment under the CLMBR and FORME brands and pending acquirer of Sportstech and Wattbike, today announced its financial results for the first quarter of 2025.The Company reported revenue of $1.4 million, a nearly 4x increase from the prior-year period. Net loss for the quarter was $6.6 million, or $1.74 per diluted share, compared with a...

Read more

BODYWELE Offers Expanded Emsculpt NEO Treatments Following FDA Clearance for Functional Wellness Use

May 19, 2025 8:00 AM

Emsculpt Neo, already known for its ability to tone muscles and reduce fat, has recently gained FDA clearance for an expanded range of therapeutic uses. With this new clearance, the technology can now be applied in clinical settings to support functional wellness, offering benefits that go beyond aesthetics to help patients improve mobility, physical strength, and overall well-being.The Emsculpt Neo treatment is now recognized for addressing...

Read more

Protagenic Therapeutics and Phytanix Announce Business Combination to form Neuroactive Biopharmaceutical Company with Six Drug Candidates in Development including Treatments for Obesity and Metabolic Disorders

May 19, 2025 7:43 AM

Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") and Phytanix Bio Inc. have entered into a definitive share exchange agreement pursuant to which the two entities will combine in an all-stock transaction (the "Combination"). The combined entity, to be called Phytanix, Inc., will bring together two pipelines focused on stress-related and CNS disorders, five preclinical assets and one clinical-stage asset.Pipeline AssetsPT-00114 (Phase...

Read more

Global Cities Named for Breaking Down Health Data Barriers and Leading EHR Connectivity in 2025 - Black Book Research

May 19, 2025 7:00 AM

A sixteen month global study by Black Book Research, drawing from more than 52,000 verified survey responses from health IT leaders, clinicians, and digital infrastructure administrators in 57 countries, has revealed the world's leading cities in achieving seamless health record exchange and EHR optimization. While a growing number of urban health systems are pushing forward with national digital transformation initiatives, only a small elite...

Read more

Cantargia Publishes Promising Preclinical Results Highlighting CAN10's Potential to Inhibit Vascular Inflammation

May 19, 2025 1:45 AM

Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced the publication of preclinical results from IL1RAP targeting antibodies in models of vascular inflammation. Cytokines dependent on IL1RAP strongly affect human endothelial cells to induce release of proinflammatory mediators, attract immune cells and increase vascular permeability. These changes can be potently blocked by antibodies targeting IL1RAP. Also, IL1RAP levels in...

Read more

DEA Marijuana Hypocrisy Exposed: MMJ Legal Drug Blocked While Cartels Thrive in Marijuana Legal States

May 18, 2025 5:00 AM

As the Drug Enforcement Administration (DEA) releases its 2025 National Drug Threat Assessment, a stunning contradiction emerges: while the DEA points fingers at states that have legalized marijuana for allegedly aiding transnational cartels, it continues to obstruct MMJ International Holdings and its subsidiaries - MMJBioPharma Cultivation and MMJ BioPharma Labs from lawfully developing cannabis based pharmaceutical drugs under full federal...

Read more

Canadian Healthcare Consumers Urge Fixes to Digital Health Shortfalls in New Survey - Black Book Research

May 17, 2025 11:30 AM

A newly released national survey from Black Book Research, conducted in April 2025, reveals that Canadian healthcare consumers are embracing digital tools like virtual care, online appointment scheduling, and patient portals, but they're also encountering persistent frustrations that risk undermining progress. As the healthcare IT community prepares for e-Health Canada 2025 (June 1-3, Toronto), these insights spotlight where vendors, providers,...

Read more

Fighting the Fire: How Emma Myers Took Her Life Back From CRPS With Help From the Spero Clinic

May 16, 2025 6:00 PM

Estimates suggest that more than 20% of the world's population suffers from pain, while each year, 10% are newly diagnosed with chronic pain. Pain has become a "silent" epidemic for which the medical community has no answers.Rowan County, N.C. native Emma Meyers had never been without extensive nerve pain since the age of 4. Instead of spending her childhood playing and having fun, Emma's mobility worsened to a point where she could no longer...

Read more

Onco-Innovations Celebrates Listing of Common Shares on Cboe Canada

May 16, 2025 6:00 PM

Onco-Innovations Limited (CSE:ONCO) ("Onco" or the "Company") is pleased to announce that it will transfer the listing of its common shares (the "Common Shares") to Cboe Canada Inc. ("Cboe Canada") from the Canadian Securities Exchange ("CSE"). Onco expects its Common Shares to begin trading on Cboe Canada on May 22, 2025 under its existing ticker symbol "ONCO", and the Company has submitted a request to voluntarily delist its Common Shares from...

Read more

Prevent-Plus Highlights Key PREVENTOGEN Infection Prevention Clinical Data Presented at the 44th Annual Surgical Infection Society Meeting

May 16, 2025 3:30 PM

Prevent-Plus, a progressive leader in the management and prevention of surgical site infections, highlights Preventogen's key scientific and clinical contributions in 2024-2025 that are shaping the future of advanced polymers for infection prevention.The results of two recent studies using Preventogen for the prevention of infections, 1) after elective surgery and 2) after the insertion of Tunneled Hemodialysis catheters, were presented at the...

Read more

BuzzRx Launches 'Bee Healthy' Scholarship Program to Empower the Next Generation of Health Leaders

May 16, 2025 1:45 PM

Prescription discount provider BuzzRx recently introduced the first-annual BuzzRx Bee Healthy Scholarship Fund, a new initiative to provide scholarships to qualified students pursuing a healthcare-related career."The next generation of health leaders will play a critical role in helping Americans across the country live healthier lives," says Matthew Herfield, co-founder and CEO of BuzzRx. "Creating a healthier nation relies on the power of...

Read more

Black Book Survey Reveals Urgent EHR Gaps as Canada’s New Government Prioritizes Digital Health Reform

May 16, 2025 9:45 AM

A new national survey by Black Book Market Research reveals that despite ongoing investments in digital health, Canada's electronic health record (EHR) systems remain fragmented, outdated, and under-optimized-posing significant risks to care quality and national health equity. The findings arrive as Prime Minister Mark Carney's newly elected Liberal government signals a strong commitment to modernizing digital infrastructure and addressing...

Read more

CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 16, 2025 8:05 AM

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the first quarter ended March 31, 2025 and provided a corporate update."Our company remains focused as tightly as ever on neuro-oncology drug development. We are off to a very rapid...

Read more

CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results

May 16, 2025 8:00 AM

CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the quarter ended March 31, 2025.Dr. Wei-Wu He, Ph.D., CASI's Chairman and Chief Executive Officer, commented, "We remained focused on advancing the development of our lead program,...

Read more

NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu

May 16, 2025 6:30 AM

NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending March 31, 2025 with the Securities and Exchange Commission (SEC) on Thursday, May 15, 2025. The report can be accessed at the SEC website (https://www.sec.gov/Archives/edgar/data/1379006/000141057825001336/nnvc-20250331x10q.htm) .NV-387 - Phase II Clinical Trial to Treat MPox Infection - Unmet Medical NeedWe...

Read more

Quarterly Report Q1 2025: Positive Outcome of Orviglance FDA Meeting in Advance of the NDA Submission

May 16, 2025 1:50 AM

Ascelia Pharma (STO:ACE) - Ascelia Pharma AB (publ) (ticker: ACE) today published its Interim Report Q1 for 2025 (January - March), which is now available on the company's website: Financial Reports - ASCELIAKEY EVENTS IN Q1 2025Three scientific abstracts with Orviglance® SPARKLE Phase 3 data accepted for presentation at the ESGAR congress 2025Extraordinary General Meeting on 25 February 2025 to adopt an employee stock option proposalNomination...

Read more

Bionxt Solutions Provides Bi-Weekly MCTO Status Report

May 15, 2025 7:30 PM

BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:XPHYF)(FSE:4XT), announces that, further to its news release dated May 1, 2025 (the "Default Announcement"), the Company's principal regulator, the British Columbia Securities Commission (the "BCSC") granted a management cease trade order (the "MCTO") on May 1, 2025, under National Policy 12-203 Management Cease Trade Orders ("NP 12-203").Pursuant to the MCTO, the Chief...

Read more

Sustainability in Surgery: Dr. Richard Birkett's Commitment to ESG Programs in Healthcare

May 15, 2025 5:15 PM

In the rapidly evolving landscape of modern healthcare, the intersection of medicine and sustainability is becoming increasingly critical. Watching this movement stands Dr. Richard Birkett, MD, MBA; a Colon and Rectal Surgeon based in Greater Boston, who is making efforts to integrate Environmental, Social, and Governance (ESG) principles into surgical practice and medical device development.Dr. Birkett is known for his clinical expertise in...

Read more

CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE

May 15, 2025 4:45 PM

CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biotech company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that the European Patent Office (EPO) has confirmed the validity of CureVac's European patent EP 4 023 755 B1 subject to amendments to specify the scope of protection. This validity decision marks the second time the EPO has ruled in favor of CureVac, having decided in...

Read more